Research Products
Research Equipment
Antibodies
Researchers from the National Institute of Allergy and Infectious Diseases (NIAID) and the University of Maryland have unveiled a groundbreaking discovery, revealing the formation of a recombinant heterodimer known as p40-CD5L by combining two known proteins, p40 and CD5L. This heterodimer's significance lies in its ability to stimulate the production of interleukin-4 (IL-4) and interleukin-10 (IL-10) by T cells, which holds great promise for addressing conditions such as allergies, asthma, and tumor immunology. Furthermore, the researchers have identified antibodies that serve dual roles in assays for detecting and quantifying p40-CD5L and as reagents for blocking its activity, opening up new avenues for research and potential therapeutic applications in the fields of immunology and healthcare.
Commercial Applications
The p40-CD5L cytokine discovery has versatile applications. It can be a therapeutic target for allergies, asthma, and tumors due to its impact on IL-4 and IL-10 production. The antibodies enable precise diagnostics, aiding in disease detection and monitoring. This technology's flexibility, including protein sequences, nucleic acids, and assays, benefits both research and clinical applications, offering opportunities for targeted therapies and improved diagnostics.
Competitive Advantages
The discovery of p40-CD5L cytokine technology presents several competitive advantages. It introduces a unique mechanism for influencing immune responses by promoting IL-4 and IL-10 production in T cells. The specific antibodies developed for detecting and blocking p40-CD5L offer precision in research and potential therapeutic applications. This comprehensive technology, encompassing protein sequences, nucleic acid embodiments, and assays, provides a versatile toolkit for advancing immunology research and healthcare solutions, making it highly competitive in the field.
